CRIPTO/GRP78 Signaling Maintains Fetal and Adult Mammary Stem Cells Ex Vivo

Benjamin T. Spike,1,* Jonathan A. Kelber,3,4 Evan Booker,2 Madhuri Kalathur,2 Rose Rodewald,1 Julia Lipianskaya,1 Justin La,1 Marielle He,2 Tracy Wright,3 Richard Klemke,3 Geoffrey M. Wahl,1 and Peter C. Gray2,*

1Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
2Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
3Department of Pathology, University of California, San Diego, La Jolla, CA 92037, USA
4Present address: Department of Biology, California State University, Northridge, CA 91330, USA
*Correspondence: bspike@salk.edu (B.T.S.), gray@salk.edu (P.C.G.)
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

SUMMARY

Little is known about the extracellular signaling factors that govern mammary stem cell behavior. Here, we identify CRIPTO and its cell-surface receptor GRP78 as regulators of stem cell behavior in isolated fetal and adult mammary epithelial cells. We develop a CRIPTO antagonist that promotes differentiation and reduces self-renewal of mammary stem cell-enriched populations cultured ex vivo. By contrast, CRIPTO treatment maintains the stem cell phenotype in these cultures and yields colonies with enhanced mammary gland reconstitution capacity. Surface expression of GRP78 marks CRIPTO-responsive, stem cell-enriched fetal and adult mammary epithelial cells, and deletion of GRP78 from adult mammary epithelial cells blocks their mammary gland reconstitution potential. Together, these findings identify the CRIPTO/GRP78 pathway as a developmentally conserved regulator of fetal and adult mammary stem cell behavior ex vivo, with implications for the stem-like cells found in many cancers.

INTRODUCTION

Somatic stem cells govern the development, maintenance, and regeneration of tissues, and their dysregulation is associated with diverse pathologies, including cancer. Given the significance of these cells both biologically and therapeutically, it is critical to define factors and signaling mechanisms that dictate their behavior, including those that define niches capable of promoting the stem cell phenotype in normal and disease settings. However, few such factors have been elucidated, and progress toward this goal has been impeded by the fact that most somatic stem cells, including those of the mammary gland, are rare and difficult to isolate and propagate ex vivo.

The mammary epithelium consists principally of lineage-restricted basal keratin-14-positive (KRT14⁺) myoepithelial cells and keratin-8-positive (KRT8⁺) luminal epithelial cells (Mikaelian et al., 2006). Although recent reports indicate extensive self-renewal within each of these lineage-committed populations (Van Keymeulen et al., 2011), classic single-cell transplant experiments indicate the presence of rare transplantable bipotent mammary stem cells (MaSCs) in the mature mammary gland (Shackleton et al., 2006). These cells can be significantly enriched through the use of cell-surface marker combinations such as CD24 and CD49f (Stingl et al., 2006). However, the functional significance of such markers to stem cell biology is often unclear, and the resulting enrichment generally remains too low to discern core molecular determinants of the stem cell state from the population at large.

In an effort to circumvent these challenges, we recently characterized a highly enriched population of stem cells from murine embryonic mammary rudiments (Spike et al., 2012). The greater purity of these fetal mammary stem cells (fMaSC) relative to their adult counterparts makes them particularly useful in the study of MaSC biology. Interestingly, we found that fMaSCs share gene expression features with certain aggressive human breast cancers that are not shared between enriched populations of adult MaSCs and the same breast cancers. This distinction may reflect intrinsic differences between the fetal and adult MaSCs or differential heterogeneity in the stem cell-enriched populations used for profiling. Alternatively, this observation may be due to critical differences in the tissue contexts from which these cells are derived, a possibility consistent with prior reports indicating an important role for microenvironmental factors in establishing and maintaining the stem cell competence of both fetal and adult mammary cells (Makarem et al., 2013; Spike et al., 2012; Vaillant et al., 2011). However, the ability of specific factors to promote the MaSC phenotype has rarely been directly demonstrated.

CRIPTO (CR-1, TDGF1) is an oncofetal, GPI-anchored/secreted signaling protein that plays key roles as a stem cell regulator (Adewumi et al., 2007; Bianco et al., 2010; Hough et al., 2009; Miharada et al., 2011). CRIPTO is...
Figure 1. ALK4L75A-Fc Inhibits Growth-Factor-like Effects of CRIPTO on Immortalized Human Mammary Epithelial Cells
(A) ALK4L75A-Fc (10 μg/ml) inhibits binding of 125I-CRIPTO to native MCF10A cells. Data from one of two independent experiments using three technical replicates are shown, with SDs.
(B) Phospho-AKT (Ser 473) or total AKT western blots on lysates from MCF10A cells treated with soluble CRIPTO (300 ng/ml), ALK4L75A-Fc, and PI3K inhibitor LY 294002 (10 μM) as indicated.

(legend continued on next page)
RESULTS

An ALK4-Based Antagonist Inhibits Growth-Factor-like Effects of Soluble CRIPTO on Mammary Epithelial Cells

We developed a CRIPTO antagonist in order to test if CRIPTO signaling is required for the maintenance of MaSCs. We took advantage of the CRIPTO binding properties of the extracellular domain (ECD) of the ACTIVIN/NODAL type I receptor ALK4 (Bianco et al., 2002; Gray and Vale, 2012; Yeo and Whitman, 2001) and the fact that a leucine to alanine substitution at amino acid 75 (L75A) disrupts ALK4/ACTIVIN binding without affecting ALK4 binding to CRIPTO (Kelber et al., 2008). Although the L75A mutation does not guarantee complete specificity of ALK4 ECD binding to CRIPTO, we reasoned that this substitution should increase the selectivity of their interaction. We previously showed that a kinase-deleted ALK4L75A protein blocks CRIPTO effects on ACTIVIN and NODAL signaling (Kelber et al., 2008), leading us to hypothesize that a soluble version of the ALK4L75A ECD would similarly block CRIPTO signaling. To test this, we fused an N-terminally Flag-tagged ALK4-ECDL75A to the Fc region of human immunoglobulin G (ALK4L75A-Fc). We purified the recombinant protein from conditioned media using affinity chromatography and confirmed its ability to bind CRIPTO in solution (Figures S1A–S1D and Supplemental Experimental Procedures available online).

Using the CRIPTO-responsive human mammary epithelial MCF10A cell line, we find that ALK4L75A-Fc effectively inhibits binding of soluble CRIPTO to intact cells and blocks CRIPTO-dependent augmentation of AKT phosphorylation (Figures 1A and 1B). This effect appears to be specific, because ALK4L75A-Fc only blocks CRIPTO-dependent AKT phosphorylation, whereas a PI3K inhibitor (LY 294002) blocks detection of both CRIPTO-induced and basal phospho-AKT (Figure 1B). As expected, and in
contrast to CRIPTO-independent ACTIVIN A signaling, NODAL treatment induces SMAD2 phosphorylation in MCF10A cells stably transduced with CRIPTO lentivirus (MCF10A-CR), but not in control cells transduced with empty vector (MCF10A-V) (Figure 1C). Both NODAL and ACTIVIN A signal via ALK4, and SMAD2 phosphorylation in response to each ligand is blocked by the ALK4/5/7 kinase inhibitor SB 431542 (Figure 1C). ALK4 L75A-Fc treatment, on the other hand, has no effect on ACTIVIN A-induced SMAD2 phosphorylation (Figure 1C), consistent with our previous demonstration that the ALK4 L75A mutation blocks ACTIVIN A binding (Kelber et al., 2008). Surprisingly, however, ALK4 L75A-Fc treatment also has no discernible effect on CRIPTO-dependent NODAL signaling in MCF10A-CR cells (Figure 1C) or on CRIPTO-dependent NODAL induction of a SMAD2-responsive luciferase reporter in 293T cells (Figure S1E). This failure of ALK4 L75A-Fc to block CRIPTO coreceptor activity is consistent with our inability to detect ALK4 L75A-Fc binding on the surface of intact CRIPTO-overexpressing 293T cells (Figure S1F).

MCF10A-CR cells secrete CRIPTO (Figure S2A) and have elevated levels of PI3K/AKT signaling relative to MCF10A-V cells (Figure S2B), leading us to test if ALK4 L75A-Fc inhibits autocrine/paracrine CRIPTO growth factor activity in these cells. We use live-cell time-course and time-lapse microscopy, respectively, to track proliferation and migration of MCF10A-CR cells and control cells (MCF10A-V). MCF10A-CR cells accumulate more rapidly than MCF10A-V cells (Figure 1D), consistent with our previous findings (Kelber et al., 2009), and these CRIPTO-expressing cells also have enhanced migration relative to control cells (Figure 1E). Treatment with ALK4 L75A-Fc inhibits the CRIPTO-dependent increases in growth (Figure 1D) and motility (Figure 1E; Figure S2C; Movies S1, S2, S3, and S4). The inhibitory effects of ALK4 L75A-Fc treatment on CRIPTO-dependent migrational velocity and persistence are similar to those of GRP78 antibody (N-20) (Figure 1E; Figure S2C) that we previously showed blocks CRIPTO/GRP78 binding (Kelber et al., 2009).

We also analyzed the effects of CRIPTO signaling and antagonism on MCF10A cells in 3D culture in the presence or absence of the reconstituted basement membrane Matrigel. Although suspension cultures have been widely used to measure the production of multicellular mammary epithelial structures called “mammospheres” (Dontu et al., 2003), Matrigel-containing mammary epithelial cultures promote the formation of differentiated, polarized acinar structures from MCF10A cells and multilayered, multi-lineage organoids from primary mammary epithelial stem cells (Debnath et al., 2003; Spike et al., 2012). MCF10A-CR cells accumulate more rapidly than MCF10A-V cells in free-floating suspension cultures, where they exhibit a greater proportion of cells with 2N-4N DNA content indicative of cycling S phase cells (Figure 1F; Figures S2D and S2E). The growth promoting effects of CRIPTO under these conditions are blocked by treatment with ALK4 L75A-Fc or LY 294002, but not SB 431542 (Figure S2D). We used methylcellulose immobilization of cells in suspension cultures to measure the size of individual spheres (Figures 1G and 1H). Consistent with the increased cell numbers observed in free-floating cultures, immobilized MCF10A-CR cells form larger, more numerous mammospheres than MCF10A-V cells, and the increased growth of the CRIPTO-expressing cells is again blocked by ALK4 L75A-Fc and LY 294002, but not by SB 431542 (Figure 1H). CRIPTO overexpression similarly promotes MCF10A colony growth in Matrigel, and this is inhibited by treatment with ALK4 L75A-Fc, whereas treatment of these cultures with NODAL neither augments CRIPTO-induced growth nor overcomes ALK4 L75A-Fc-mediated inhibition of CRIPTO-induced growth (Figure S2F). Altogether, these results indicate that soluble CRIPTO promotes proliferation and migration of mammary epithelial cells and that this can be blocked by ALK4 L75A-Fc.

**CRIPTO/GRP78 Expression and Function in fMaSCs**

Our data show that MCF10A cells respond to soluble CRIPTO signaling in multiple contexts, including 3D growth assays that are similar to those used previously to evaluate stem cell-like cellular behaviors (Donut et al., 2003). We also previously demonstrated that soluble CRIPTO activates the PI3K/AKT pathway in MCF10A cells by binding to cell-surface GRP78 (Kelber et al., 2009). These findings, together with reports that CRIPTO and GRP78 cooperatively regulate stem cell function in other contexts, prompted us to test if CRIPTO and GRP78 are expressed in murine mammary tissue and if the CRIPTO/GRP78 pathway is operative in primary mammary stem/progenitor cells. We first investigated the pattern of CRIPTO and GRP78 expression in embryonic day 18.5 (E18.5) mouse mammary rudiments, because they provide a rich source of robust stem cell activity (Spike et al., 2012). We find GRP78 to be expressed throughout the mammary rudiment, with the most intense and distinct staining coinciding with the burgeoning, arborized mammary epithelium, demarcated here by co-staining with antibodies to KRT8 (Figures 2A and 2B). By contrast, CRIPTO staining is more diffuse and distributed throughout the rudiment, with significant staining in the fetal mammary stroma and areas within and adjacent to the GRP78-positive and KRT8-positive epithelium. Interestingly, we observe intense CRIPTO staining at or near the termini of the arborized mammary rudiment, where it overlaps with both the condensed mesenchyme adjacent to the epithelium and epithelial cells that stain prominently for
GRP78 (Figures 2A and 2B). *CRIPTO* mRNA was detected in fMaSCs but is more highly expressed in a variety of other cell populations isolated from the fetal mammary microenvironment, including putative adipose precursor cells that resist centrifugation during rudiment processing (“Fat”), myeloid cells (Lin⁻CD11b⁺F4/80⁻), and non-myeloid lineage-positive cells (CD11b⁺F4/80⁻) (Figure 2C). *CRIPTO* message is also present in other stromal cells (fStromal; Lin⁻/CD24low) that likely include mammary tissue fibroblasts (Figure 2C). Costaining of the mammary rudiment for the macrophage marker F4/80 confirms colocalization of *CRIPTO* protein with not only macrophages but also other nonmacrophage stromal components adjacent to the fetal mammary epithelium (Figure 2D). Thus, *CRIPTO* is expressed in multiple cell types within the MaSC microenvironment, leading us to reason that soluble secreted *CRIPTO* may govern fMaSC behavior as an autocrine/paracrine growth factor.
Our previous studies indicating that CRIPTO signals via cell-surface GRP78 led us to test if GRP78 is expressed on the surface of fMaSCs (Lin−CD24high) and if these cells respond to soluble CRIPTO in a GRP78-dependent manner. We analyzed dissociated cells from E18.5 mammary rudiments by flow cytometry and discovered that >80% of the fMaSC population is GRP78 positive (Figure 2E). Furthermore, when we treat fMaSC-derived Matrigel colonies with soluble CRIPTO, we observe increased AKT phosphorylation that is blocked by treatment with ALK4L75A-Fc or LY 294002 (Figure 2F). This increase in AKT phosphorylation is also blocked by N-20, indicating that CRIPTO signals via cell-surface GRP78 in these cells (Figure 2F). Soluble CRIPTO treatment also increases the proportion of K667+ cells relative to untreated cells in 2D culture, and this effect was once again blocked by ALK4L75A-Fc treatment (Figure 2G). Thus, multiple cell types within the fetal mammary rudiment produce CRIPTO, and it can act on cells within the fMaSC population.

**CRIPTO/GRP78 Signaling Promotes Maintenance of fMaSCs Ex Vivo**

To explore the consequences of CRIPTO signaling in MaSCs further, we examined its effects on growth, self-renewal, and differentiation in fMaSC cultures. We previously reported that fMaSCs grown in media that promotes their differentiation give rise to a high proportion of bilineage organoids containing both KRT8−KRT14+ luminal cells and KRT14−KRT8+ myoepithelial cells by 7–12 days of culture (Spike et al., 2012). At 5 days of culture, organoids grown in this differentiation promoting media typically contain a fraction of cells coexpressing KRT8 and KRT14 (Figure 3A, top left, yellow arrows, and Figure 3B). Supplementation of these cultures with CRIPTO or ALK4L75A-Fc has opposing effects on the fraction of organoids containing double-positive (KRT8−KRT14+) cells and on the amount of double-positive area per organoid (Figure 3A, left panels, and Figure 3B; Figures S3A and S3B). Specifically, CRIPTO treatment increases the proportion of double-positive area per organoid while ALK4L75A-Fc treatment substantially reduces colony-forming efficiency and the growth of large colonies (>100 μm) is almost completely abolished (Figure 3D). Conversely, addition of CRIPTO can support a round of serial passage of fMaSC-derived cells, even under conditions that strongly favor differentiation (Figure 3D). We note that clonogenicity of fetal mammary cells was recently shown to be enhanced by unidentified factors secreted by 3T3 fibroblasts in coculture (Makarem et al., 2013). We find that 3T3 cells express CRIPTO protein (Figure S3D) and that their ability to enhance clonogenicity of fetal mammary cells in coculture can be partially blocked by treatment with either ALK4L75A-Fc or CRIPTO antibodies (Figure S3E). This result is consistent with our results using recombinant proteins and further highlights the potential for non-cell-autonomous CRIPTO regulation of fMaSCs.

**GRP78 Is a Critical Functional Marker and Cell-Surface Determinant of CRIPTO-Responsive MaSCs**

We examined CRIPTO and GRP78 expression in the adult mammary gland and identified marked immunoreactivity for both proteins that overlaps with the morphologically distinct mammary ductal epithelium and adjacent adipose tissue (Figure 4A). Immunofluorescent colocalization studies confirm overlapping CRIPTO and GRP78 staining.
in these cell types, including elevated staining in adipose and a subset of mammary epithelial cells (Figure 4B). To determine whether adult MaSCs require GRP78, we used CRE-mediated recombination and excision of GRP78 alleles together with mammary gland reconstitution experiments. In these experiments, cells harboring CRE-expressing virus failed to reconstitute mammary ductal trees in each of nine transplant attempts (zero out of nine), while an equivalent number of cells transduced with control virus robustly repopulate the gland (three out of three) (Figure 4A). Furthermore, cells isolated from control outgrowths exhibit cell-surface GRP78 and contain both the luminal and myoepithelial fractions (Figure S4C). In contrast, we only occasionally recover a low number of presumptive mammary epithelial cells from transplants of GRP78Fl/Fl cells infected with CRE virus. These cells...
Figure 4. GRP78 Is Required for MaSC Activity and Marks a CRIPTO-Responsive Stem Cell-Enriched Population of Adult Mouse Mammary Epithelial Cells

(A) Immunohistochemical localization of CRIPTO and GRP78 in adult mouse mammary tissue. Inset: secondary antibody alone (2nd).
(B) CRIPTO and GRP78 proteins colocalize in stromal areas including adipose (f, fat) and in epithelial structures (e), where a subset of cells display elevated staining for both markers (white arrows).
(C) Repopulation rate of de-epithelialized mammary glands inoculated with 500 GRP78-floxed epithelial cells transduced with Ad-CRE/GFP- or Ad-GFP and sorted for GFP. Each circle represents one recipient mammary gland. Filled circles indicate >50% fat pad filling.
(D) Flow cytometric analysis of wild-type adult mouse mammary cells stained for CD24 and GRP78 (lineage excluded) indicating the presence of cell-surface GRP78 in adult mammary epithelia and demarcating the GRP78high and GRP78low populations (left). Antibodies to CD49f were also incorporated (right), and cells positive for GRP78 and CD24 were gated to generate a population density graph (red lines) superimposed on the CD24/CD49f staining. The standard positions of the CFC, MYO, and MRU populations (Stingl et al., 2006) are indicated.
(E) Colonies grown from single cells sorted into individual wells in 96-well plates. Luminal, organoid, and myoepithelial morphologies were distinguishable (left). The number of each type of clonal outgrowth deriving from single GRP78low and GRP78high cells in one representative experiment (of three similar experiments) was quantified according to morphology (right).
(F) Confocal micrographs showing the keratin distribution observed in representative colonies grown from cells sorted using CD24 and GRP78. GRP78low cells predominantly expressed either KRT8 or KRT14, while GRP78high cultures frequently exhibited KRT8/KRT14+ outgrowths. Representative organoid (i), luminal (ii), and myoepithelial (iii) colonies are shown. Color panels show individual fluorophores separately for the organoid (i, insets). Scale bars represent 100 μm.

(legend continued on next page)
appear restricted to the mature luminal fraction, lack detectable cell-surface GRP78, and do not give rise to colonies when cultured in vitro (Figure S4A; data not shown). These data indicate that GRP78 is required for MaSC activity as measured by transplantation assays.

Next, we sought to examine the role of cell-surface GRP78 as an adult MaSC marker and as a MaSC regulator specifically in its capacity as a mediator of CRIPTO signaling. We isolated CD24-positive mammary epithelial cells with either high (GRP78-high) or low (GRP78-low) levels of cell-surface GRP78 from wild-type mice (Figure 4D, left panel). A substantial portion of adult mammary epithelial cells was GRP78-high (19.4% ± 3.4% of the CD24-positive fraction), though the proportion was considerably lower than in fetal mammary epithelia (Figure 3D). In costained samples, we observe that while the GRP78-high population overlaps partially with the previously reported luminal colony-forming cell (CFC) and myoepithelial (MYO) populations, it overlaps most precisely with the stem cell-enriched CD24-medCD49-high mammary repopulating unit (MRU) fraction (Figure 4D, right panel) (Stingl et al., 2006). While cells from both the GRP78-high and GRP78-low fractions produce clonal outgrowths in Matrigel culture, those derived from the GRP78-high population are much more likely to give rise to colonies containing multiple cell layers (Figure 4E; organoids) and to stain positive for both KRT14 and KRT8 (Figure 4F; Figure S4B). In these assays, the most frequently observed and morphologically distinguishable colony types include those that appear luminal, composed of a single peripheral cell layer surrounding an open lumen, small myoepithelial colonies (usually < 16 cells), and distinctive, multilayered organoids containing both luminal and myoepithelial cell types (Figures 4E and 4F) (Spike et al., 2012; Stingl et al., 2006). Importantly, these morphologically distinct colony types are produced in cultures both when single cells were plated in individual wells (Figure 4E) and when cells are plated at single-cell densities (1,000 cells per 0.32 cm²) (Figure 4F; data not shown) (Spike et al., 2012). Thus, the substantially higher proportion of organoids and KRT14+KRT8+ double-positive colonies formed from the GRP78-high population (Figures 4E and 4F; Figure S4B) suggests that the GRP78-high population is enriched for bipotent stem/progenitor cells. In contrast, GRP78-low cells predominantly give rise to small myoepithelial (KRT14+KRT8+) or monolayered luminal (KRT14–KRT8+) outgrowths (Figures 4E and 4F; Figure S4B).

As an independent criterion for assessing the stem cell content of the GRP78-high population, we transplanted CD24-medGRP78-high and CD24-medGRP78-low mammary epithelial cell populations into cleared mammary fat pads at limiting dilutions. The results clearly indicate that the CD24-medGRP78-high cells reconstitute mammary glands more efficiently the CD24-medGRP78-low cells (Figure 4G; Figures S4C–S4E). We estimate the frequency of mammary gland-reconstituting units to be approximately 1/26 in the GRP78-high cells (90% confidence interval [CI], 1/15–45.4; extreme limiting dilution analysis [ELDA]) versus approximately 1/152 in the GRP78-low population (90% CI, 1/67.0–346.2; ELDA) (Figure 4G; Figure S4E). This correlates with a significant enrichment (p < 0.01; ELDA) of stem cell activity in the GRP78-high fraction relative to the GRP78-low cells (Figure 4G; Figures S4C–S4E). Outgrowths from transplanted GRP78-high cells resemble endogenous mammary glands in FACS analyses including the presence of GRP78-high cells within the CD24 expressing mammary epithelium (Figure S4F). Significantly, the self-renewal potential of these cells is evident in their capacity to reconstitute fully arborized mammary epithelial outgrowths in tertiary transplants that respond normally to pregnancy (Figure S4G). We also identify a diffuse, small, and variable population of GRP78 “superpositive” (GRP78-high+) cells with intermediate performance in stem cell assays (Figures S4D and S4E).

Because CRIPTO signaling promotes serial passage of fMaSCs ex vivo (Figure 3D), we tested the effects of this pathway on cultures of adult GRP78-high and GRP78-low mammary epithelial populations. Consistent with its greater enrichment for cells with a bipotent stem cell phenotype (Figures 4E–4G; Figure S4B), the GRP78-high population exhibits greatly enhanced potential for serial colony formation relative to GRP78-low cells, especially over increasing serial passage number in Matrigel (Figure 4H; Figure S4H). Furthermore, serial passage of GRP78-high cells is significantly enhanced by CRIPTO treatment (Figure 4H) and, similar to what was observed with fMaSCs, serial colony formation of adult GRP78-high cells is also inhibited by ALK4(-/-)-Fc treatment, suggesting that endogenous
soluble CRIPTO maintains the self-renewal potential of these cells. By contrast, GRP78\textsuperscript{low} cells are largely refractory to treatment with CRIPTO or ALK4\textsuperscript{L75A}-Fc (Figure 4H), consistent with a requirement for surface GRP78 for CRIPTO signaling (Kelber et al., 2009). Together, these data support a role for soluble CRIPTO in maintaining the stem cell phenotype of GRP78\textsuperscript{high} mammary epithelial cells.

The data are consistent with a model (Figure 4I) in which surface GRP78 is a functional MaSC marker. In this model, the most undifferentiated MaSC state depends on endogenous CRIPTO signaling, because treatment with ALK4\textsuperscript{L75A}-Fc leads to loss of multipotency and eventual rundown of self-renewal in serial passage. In addition, a subset of cells, at least in the adult context, lacks endogenous CRIPTO but can respond to exogenous soluble CRIPTO with increased serial clonogenicity or self-renewal. Thus, according to this model, CRIPTO treatment shifts cells to a more primitive, stable, or competent stem cell state while ALK4\textsuperscript{L75A}-Fc treatment makes them susceptible to commitment and differentiation.

**DISCUSSION**

Extracellular signaling factors play critical roles in regulating the balance between stem cell self-renewal and differentiation (Jones and Wagers, 2008; Spradling et al., 2001). In the present study, we identify CRIPTO as one such factor that promotes multipotency and maintains gland reconstitution potential of mammary stem/progenitor cells ex vivo. We also show that the CRIPTO cell-surface receptor GRP78 is required for MaSC activity and CRIPTO responsiveness. Thus, CRIPTO and GRP78 are shared determinants of both fetal and adult mammary stem/progenitor cells pointing to a developmentally conserved role for the CRIPTO/GRP78 pathway in maintenance of the MaSC state.

**ALK4\textsuperscript{L75A}-Fc Identifies Soluble CRIPTO as a MaSC Factor**

ALK4\textsuperscript{L75A}-Fc selectively targets soluble CRIPTO and blocks CRIPTO-induced PI3K/AKT signaling, indicating that CRIPTO’s growth factor-like activity is essential for maintenance of MaSC properties in the contexts we analyzed. Miharada et al. (2011) similarly showed that soluble CRIPTO regulates hematopoietic stem cells (HSC) via the PI3K/AKT pathway independent of SMAD2/3 signaling. However, although our results uncover a critical role for soluble CRIPTO growth-factor-like signaling in regulating MaSC behavior, they do not exclude a role for CRIPTO coreceptor function. Indeed, NODAL, which requires CRIPTO or a related coreceptor, may act on fMaSCs during development in vivo, because it is expressed in fetal mammary stroma (Spike et al., 2012).

ALK4\textsuperscript{L75A}-Fc treatment alone is sufficient to cause MaSC differentiation and loss of self-renewal potential ex vivo, suggesting that endogenously secreted CRIPTO sustains the clonogenicity and multipotency of mammary epithelial cells in maintenance media and in 3T3 fibroblast cocultures. Consistent with this, CRIPTO treatment inhibits lineage commitment of cells in organoid culture and increases their serial colony formation and transplantation capacity. Therefore, CRIPTO acts as an extrinsic, soluble regulator of MaSC function in vitro, raising the possibility that it may function similarly as an autocrine/paracrine stem cell factor in vivo. In support of such a role, we show that GRP78 is prominently expressed throughout the ductal epithelium within the fetal mammary rudiment while CRIPTO is concentrated near the termini of the epithelial tree and the mesenchyme surrounding these termini where stem cell activity may be focused (Kenney et al., 2001). CRIPTO expression is low in fMaSCs but higher in a variety of nonepithelial cells of the mammary rudiment such as fat cells and macrophage/myeloid cells that could mark potential niche sources of secreted CRIPTO. Adipose tissue has been previously reported to express CRIPTO (Andersson et al., 2008) and constitutes the natural environment for growth and development of the mammary ductal epithelium (Veltmaat et al., 2003). Myeloid cells, including macrophages, may also provide soluble CRIPTO for stem cell regulation, because they comprise important niche components in other systems and are required for effective mammary reconstitution (Ehninger and Trumpp, 2011; Gyorki et al., 2009).

**Cell-Surface GRP78 Is a Developmentally Conserved Marker of Fetal and Adult MaSCs**

Our data identify cell-surface GRP78 as an enrichment marker of mammary stem/progenitor cells. CRIPTO and GRP78 are coexpressed in the adult mammary gland, and cell-surface GRP78 correlates with the stem cell-surface markers CD24 and CD49f (Stingl et al., 2006). Bipotent stem/progenitor cells, though rare in the adult gland, are relatively plentiful in the sorted GRP78\textsuperscript{high} population. GRP78\textsuperscript{high} cells are also selectively responsive to CRIPTO signaling, because CRIPTO and ALK4\textsuperscript{L75A}-Fc had opposing effects on their serial colony growth and neither treatment significantly affected the GRP78\textsuperscript{low} population. Interestingly, the percentage of GRP78\textsuperscript{high} cells is greater in the fetal than in the adult mammary gland, in agreement with the larger percentage of stem cells in the fetal mammary gland than in the adult (Spike et al., 2012). However, despite its ability to augment serial colony formation in cultures derived from GRP78\textsuperscript{high} adult cells, CRIPTO
treatment only has a modest effect on serial colony formation of MaSCs in maintenance media. It is possible that CRIPTO growth-factor-like signaling is maximally activated in newly isolated fetal, but not adult, stem cells. This would explain the profound ability of the CRIPTO antagonist ALK4L75A-Fc to inhibit MaSC maintenance despite the lack of a more profound effect of CRIPTO treatment on these cells. This activity appears to be more rapidly lost in stronger differentiation-promoting contexts, unveiling a clear effect of exogenous CRIPTO in sustaining a limited capacity for serial passage.

**CRIPTO/GRP78 Signaling as a General Regulator of the Stem Cell State**

CRIPTO is an established regulator of embryonic stem cells and induced pluripotent stem cells (Bianco et al., 2010), whereas GRP78 is a necessary mediator of CRIPTO signaling in human embryonic stem cells (Kelber et al., 2009) and promotes survival and proliferation of the murine inner cell mass cells that are precursors of murine embryonic stem cells (Luo et al., 2006). In the adult, GRP78 was recently reported to be essential for maintenance of adult intestinal stem cells (Heijmans et al., 2013) and conditional deletion of GRP78 in the hematopoietic system suppressed PI3K activity and decreased HSC number (Wey et al., 2012a, 2012b). Furthermore, CRIPTO was shown to be a hypoxic niche-associated factor that maintains the stem cell state and transplantability of GRP78^high^ HSCs cultured ex vivo (Miharada et al., 2011). Although the mechanistic basis of CRIPTO/GRP78 signaling is still emerging, it has been shown that cell-surface localization of GRP78 often correlates with its overall expression level and occurs under stress conditions in which GRP78 is induced (Zhang et al., 2010). Therefore, although the stem cell niche remains poorly defined in the mammalian gland, our results suggest that conditions known to increase the levels of GRP78 and/or CRIPTO such as hypoxia, nutrient deprivation, and endoplasmic reticulum stress could impact stem cell maintenance, expansion, and induction during normal mammary gland development and in homeostasis. Similarly, other signals from within the MaSC microenvironment likely intersect with CRIPTO and GRP78. For instance, Wnt signaling induces CRIPTO expression (Morkel et al., 2003) and has been reported to promote MaSC self-renewal in vitro (Zeng and Nusse, 2010). Our recent demonstration that MaSCs share a high degree of similarity with certain human breast cancers (Spike et al., 2012) is consistent with other evidence suggesting that tumor initiation, aggressiveness, and recurrence correlate with developmentally primitive states that are associated with cellular plasticity and increased stem cell disposition (Ben-Porath et al., 2008; Mizuno et al., 2010; Spike and Wahl, 2011). The results presented here show that CRIPTO/GRP78 signaling increases proliferation and maintains the potency of MaSCs ex vivo and raise the possibility that this pathway may be involved in promoting stem cell-like states in cancer, especially because expression of CRIPTO and GRP78 has been correlated with breast cancer progression and decreased patient survival (Dong et al., 2008; Gong et al., 2007; Lee, 2007). The stress-related cues that increase the expression of CRIPTO and GRP78 are prevalent in cancer and might specifically promote stem cell properties via increased CRIPTO/GRP78 signaling (Miharada et al., 2011; Zhang et al., 2010). In this regard, the ALK4L75A-Fc CRIPTO antagonist described here would have potential as a stem cell-directed cancer therapeutic.

**EXPERIMENTAL PROCEDURES**

See Supplemental Information for additional details.

**Reagents**

ALK4L75A-Fc was produced in 293T cells and purified by sequential protein-A and Flag affinity chromatography from conditioned media. Recombinant mouse CRIPTO (R&D Systems) was iodinated as previously described (Kelber et al., 2009). The following antibodies were used: CRIPTO (Abcam), GRP78 (N-20, Santa Cruz Biotechnology), KRT14 (AF-64, Covance), KRT8 (Troma-1, DSHB), F4/80 (BM8, eBioscience), Ki67 (B56, BD). Polyclonal rabbit antibodies directed against amino acids 19–39 of human GRP78 were described (Kelber et al., 2009). The following antibodies were used: CRIPTO (Abcam), GRP78 (N-20, Santa Cruz Biotechnology). The A3-luciferase reporter assay has been described previously (Gray et al., 2003; Kelber et al., 2008). GRP78 floxed mice were provided by Amy Lee (University of Southern California).

**Media**

MCF10A media was composed of Dulbecco’s modified Eagle’s medium/F12 with 5% horse serum, 10 μg/ml insulin, 20 ng/ml epidermal growth factor, 100 ng/ml cholaera toxin, 0.5 μg/ml hydrocortisone, and 10 μg/ml ciprofloxacin. Maintenance media was composed of MCF10A media with 1x B27 supplement (Invitrogen). Differentiation media was composed of Epicult-B mouse media containing B supplement (Stem Cell Technologies), recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, and heparin, as previously described (Spike et al., 2012), with ciprofloxacin 10 μg/ml.

**Cell Preparation and Culture**

All animal care and procedures were approved and monitored by an Institutional Animal Care and Use Committee. MCF10A cells were cultured free floating in CnT-27 media or immobilized in MCF10A media with 2% Matrigel or 1% methylcellulose. Primary cells were cultured, sorted, cultured, and stained as previously described (Spike et al., 2012) using the indicated media. 3T3 cocultures were adapted from Makarem et al. (2013).
Assays
Proliferation in 2D was quantified on a Celigo microplate cytomter (Cyntellect). Migrational dynamics were tracked using time-lapse microscopy and Metamorph Imaging software on 2D cultures on Matrigel. DNA content was measured by Hoechst staining. mRNA abundance was measured using Superscript III (Life Technologies) and TaqMan assays Mm03024051_g1 and Mm01324427_m1 (Applied Biosciences). Mammary transplantation analyses were conducted as previously described (Spike et al., 2012). Organoid transplants used 20 organoids each by dilution. Western blotting and quantitation of cell-surface proteins by intact cell ELISA have also been previously described (Gray et al., 2003; Kelber et al., 2008).

Statistics
Data are presented as means and SDs with p values derived from pairwise Student’s t tests, except where otherwise noted. ELDA (http://bioinf.wehi.edu.au/software/elda) was used to estimate stem cell frequencies.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, four figures, and four movies and can be found with this article online at http://dx.doi.org/10.1016/j.stemcr.2014.02.010.

ACKNOWLEDGMENTS
We thank Y. Zheng, L. Mack, J. Fitzpatrick, and J. Nguyen for technical assistance and equipment, J. Green and L. Bilezikjian for careful reading of the manuscript and helpful comments, and S. Ganley and D. Doan for administrative assistance. This work was supported by the Clayton Medical Research Foundation, The Breast Cancer Research Foundation, DoD Award number W81XWH-10-1-0891, Cancer Center Core grant P30 CA014195, and the Leona M. and Harry B. Helmsley Charitable Trust (#2012PG-MED002). This manuscript is dedicated to Wylie Vale in remembrance of his wisdom, humor, and irrepressible enthusiasm for science.

Received: August 21, 2013
Revised: February 22, 2014
Accepted: February 24, 2014
Published: April 3, 2014

REFERENCES
Adewumi, O., Aflatoonian, B., Ahrlund-Richter, L., Amit, M., Andrews, P.W., Beighton, G., Bello, P.A., Benvenisty, N., Berry, L.S., Bevan, S., et al.; International Stem Cell Initiative (2007). Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat. Biotechnol. 25, 803–816.
Andersson, O., Korach-Andre, M., Reissmann, E., Ibañez, C.F., and Bertolino, P. (2008). Growth/differentiation factor 3 signals through ALK7 and regulates accumulation of adipose tissue and diet-induced obesity. Proc. Natl. Acad. Sci. USA 105, 7252–7256.
Ben-Porath, I., Thomson, M.W., Carey, V.J., Ge, R., Bell, G.W., Regev, A., and Weinberg, R.A. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499–507.
Bianco, C., Adkins, H.B., Wechselberger, C., Seno, M., Normanno, N., De Luca, A., Sun, Y., Khan, N., Kenney, N., Ebert, A., et al. (2002). Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol. Cell. Biol. 22, 2586–2597.
Bianco, C., Strizzi, L., Mancino, M., Watanabe, K., Gonzales, M., Hamada, S., Raafat, A., Sahlah, L., Chang, C., Sotgia, F., et al. (2008). Regulation of Cripto-1 signaling and biological activity by caveolin-1 in mammary epithelial cells. Am. J. Pathol. 172, 345–357.
Bianco, C., Rangel, M.C., Castro, N.P., Nagaoka, T., Rollman, K., Gonzales, M., and Salomon, D.S. (2010). Role of Cripto-1 in stem cell maintenance and malignant progression. Am. J. Pathol. 177, 532–540.
Debnath, J., Muthuswamy, S.K., and Brugge, J.S. (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256–268.
Dong, D., Ni, M., Li, J., Xiong, S., Ye, W., Virrey, J.J., Mao, C., Ye, R., Wang, M., Pen, L., et al. (2008). Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 68, 498–505.
Dontu, G., Abdallah, W.M., Foley, J.M., Jackson, K.W., Clarke, M.F., Kawamura, M.J., and Wicha, M.S. (2003). In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253–1270.
Ehninger, A., and Trump, A. (2011). The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J. Exp. Med. 208, 421–428.
Gong, Y.P., Yarrow, P.M., Carmalt, H.L., Kwun, S.Y., Kennedy, C.W., Lin, B.P., Xing, P.X., and Gillett, D.J. (2007). Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. Eur. J. Surg. Oncol. 33, 438–443.
Gray, P.C., and Vale, W. (2012). Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis. FEBS Lett. 586, 1836–1845.
Gray, P.C., Harrison, C.A., and Vale, W. (2003). Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc. Natl. Acad. Sci. USA 100, 5193–5198.
Gyorki, D.E., Asselin-Labat, M.L., van Rooijen, N., Lindeman, G.J., and Visvader, J.E. (2009). Resident macrophages influence stem cell activity in the mammary gland. Breast Cancer Res. 11, R62.
Heijmans, J., van Lindt de Jeude, J.E., Koo, B.K., Rosekrans, S.L., Wielenga, M.C., van de Wetering, M., Ferrante, M., Lee, A.S., Onderwater, J.J., Paton, J.C., et al. (2013). ER stress causes rapid loss of intestinal epithelial stemness through activation of the unfolded protein response. Cell Rep. 3, 1128–1139.
Hough, S.R., Laslett, A.L., Grimmond, S.B., Kolle, G., and Pera, M.E. (2009). A continuum of cell states spans pluripotency and lineage commitment in human embryonic stem cells. PLoS ONE 4, e7708.
Jones, D.L., and Wagers, A.J. (2008). No place like home: anatomy and function of the stem cell niche. Nat. Rev. Mol. Cell Biol. 9, 11–21.

Kelber, J.A., Shani, G., Booker, E.C., Vale, W.W., and Gray, P.C. (2008). Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal. J. Biol. Chem. 283, 4490–4500.

Kelber, J.A., Panopoulos, A.D., Shani, G., Booker, E.C., Belmonte, J.C., Vale, W.W., and Gray, P.C. (2009). Blockade of Cripto binding to cell surface GRP78 inhibits oncopgenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene 28, 2324–2336.

Kenney, N.J., Huang, R.P., Johnson, G.R., Wu, J.X., Okamura, D., Matheny, W., Kordon, E., Gullick, W.J., Plowman, G., Smith, G.H., et al. (1995). Detection and location of amphiregulin and Cripto-1 expression in the developing postnatal mouse mammary gland. Mol. Reprod. Dev. 41, 277–286.

Kenney, N.J., Smith, G.H., Lawrence, E., Barrett, J.C., and Salomon, D.S. (2001). Identification of Stem Cell Units in the Terminal End Bud and Duct of the Mouse Mammary Gland. J. Biomed. Biotechnol. J., 133–143.

Lee, A.S. (2007). GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 67, 3496–3499.

Luo, S., Mao, C., Lee, B., and Lee, A.S. (2006). GRP78/Bip is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol. Cell. Biol. 26, 5688–5697.

Makarem, M., Kannan, N., Nguyen, L.V., Knapp, D.J., Balani, S., Prater, M.D., Stingl, J., Raouf, A., Nemirovsky, O., Eirew, P., and Eaves, C.J. (2013). Developmental changes in the in vitro activated regenerative activity of primitive mammary epithelial cells. PLoS Biol. 11, e1001630.

Mihara, K., Karlsson, G., Rehn, M., Röby, E., Siva, K., Cammenga, J., and Karlsson, S. (2011). Cripto regulates hematopoietic stem cells as a hypoxic-niche-related factor through cell surface receptor GRP78. Cell Stem Cell 9, 330–344.

Miakailian, I., Hovich, M., Silva, K.A., Burzenski, L.M., Shultz, L.D., Ackert-Bicknell, C.L., Cox, G.A., and Sundberg, J.P. (2006). Expression of terminal differentiation proteins defines stages of mouse mammary gland development. Vet. Pathol. 43, 36–49.

Mizuno, H., Spike, B.T., Wahl, G.M., and Levine, A.J. (2010). Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc. Natl. Acad. Sci. USA 107, 22745–22750.

Morkel, M., Huelskens, J., Wakamiya, M., Ding, J., van de Wetering, M., Clevers, H., Taketo, M.M., Behringer, R.R., Shen, M.M., and Birchmeier, W. (2003). Beta-catenin regulates Cripto- and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. Development 130, 6283–6294.

Rangel, M.C., Karasawa, H., Castro, N.P., Nagaoka, T., Salomon, D.S., and Bianco, C. (2012). Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer. Am. J. Pathol. 180, 2188–2200.

Shackleton, M., Vaillant, F., Simpson, K.J., Stingl, J., Smyth, G.K., Asselin-Labat, M.L., Wu, L., Lindeman, G.J., and Visvader, J.E. (2006). Generation of a functional mammary gland from a single stem cell. Nature 439, 84–88.

Shani, G., Fischer, W.H., Justice, N.J., Kelber, J.A., Vale, W., and Gray, P.C. (2008). GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth. Mol. Cell. Biol. 28, 666–677.

Spike, B.T., and Wahl, G.M. (2011). p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes Cancer 2, 404–419.

Spike, B.T., Engle, D.D., Lin, J.C., Cheung, S.K., La, J., and Wahl, G.M. (2012). A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell 10, 183–197.

Spradling, A., Drummond-Barbosa, D., and Kai, T. (2001). Stem cells find their niche. Nature 414, 98–104.

Stingl, J., Eirew, P., Ricketson, I., Shackleton, M., Vaillant, F., Choi, D., Li, H.I., and Eaves, C.J. (2006). Purification and unique properties of mammary epithelial stem cells. Nature 439, 993–997.

Vaillant, F., Lindeman, G.J., and Visvader, J.E. (2011). Jekyll or Hyde: does Matrigel provide a more or less physiological environment in mammary repopulating assays? Breast Cancer Res. 13, 108.

Van Keymeulen, A., Rocha, A.S., Ousset, M., Beck, B., Bouvencourt, G., Rock, J., Sharma, N., Dekoninck, S., and Blanpain, C. (2011). Distinct stem cells contribute to mammary gland development and maintenance. Nature 479, 189–193.

Veltmaat, J.M., Mailleux, A.A., Thiery, J.P., and Belluscio, S. (2003). Mouse embryonic mammogenesis as a model for the molecular regulation of pattern formation. Differentiation 71, 1–17.

Wey, S., Luo, B., and Lee, A.S. (2012a). Acute inducible ablation of GRP78 reveals its role in hematopoietic stem cell survival, lymphogenesis and regulation of stress signaling. PLoS ONE 7, e39047.

Wey, S., Luo, B., Tseng, C.C., Ni, M., Zhou, H., Fu, Y., Bhojwani, D., Carroll, W.L., and Lee, A.S. (2012b). Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogetic signaling. Blood 119, 817–825.

Yeo, C., and Whitman, M. (2001). Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol. Cell 7, 949–957.

Zeng, Y.A., and Nusse, R. (2010). Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 6, 568–577.

Zhang, Y., Liu, R., Ni, M., Gill, P., and Lee, A.S. (2010). Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP. J. Biol. Chem. 285, 15065–15075.